Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
CPT: Pharmacometrics & Systems Pharmacology
|
May 8, 2024
Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales
Martijn van Noort, Martijn Ruppert
CPT: Pharmacometrics & Systems Pharmacology
|
September 11, 2024
A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration
Jan Berkhout, Dave Fairman, Martijn van Noort, et al.
Accident; Analysis and Prevention
|
May 19, 2016
Can cyclist safety be improved with intelligent transport systems?
Anne Silla, Lars Leden, Pirkko Rämä, et al.
The AAPS Journal
|
March 27, 2025
The Drug Titration Paradox in the Presence of Intra-Individual Variation: Can we Estimate the True Concentration-Effect Relationship?
Sebastiaan C Goulooze, Elke H J Krekels, Catherijne A J Knibbe, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development
Martijn van Noort, Martijn Ruppert, Joost DeJongh, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 19, 2023
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
Jon Collins, Martijn van Noort, Chetan Rathi, et al.
Clinical Pharmacokinetics
|
May 4, 2022
Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
Sebastiaan Camiel Goulooze, Hiddo J L Heerspink, Martijn van Noort, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
September 15, 2020
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease
Sven Hoefman, Nelleke Snelder, Martijn van Noort, et al.
Clinical Pharmacology and Therapeutics
|
January 29, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease
Kelly M Mahar, Martijn van Noort, Paul van den Berg, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 2025
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia
Kelly M Mahar, Shuying Yang, Brendan Johnson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
CPT: Pharmacometrics & Systems Pharmacology
|
May 8, 2024
Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales
Martijn van Noort, Martijn Ruppert
CPT: Pharmacometrics & Systems Pharmacology
|
September 11, 2024
A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration
Jan Berkhout, Dave Fairman, Martijn van Noort, et al.
Accident; Analysis and Prevention
|
May 19, 2016
Can cyclist safety be improved with intelligent transport systems?
Anne Silla, Lars Leden, Pirkko Rämä, et al.
The AAPS Journal
|
March 27, 2025
The Drug Titration Paradox in the Presence of Intra-Individual Variation: Can we Estimate the True Concentration-Effect Relationship?
Sebastiaan C Goulooze, Elke H J Krekels, Catherijne A J Knibbe, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development
Martijn van Noort, Martijn Ruppert, Joost DeJongh, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 19, 2023
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
Jon Collins, Martijn van Noort, Chetan Rathi, et al.
Clinical Pharmacokinetics
|
May 4, 2022
Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
Sebastiaan Camiel Goulooze, Hiddo J L Heerspink, Martijn van Noort, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
September 15, 2020
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease
Sven Hoefman, Nelleke Snelder, Martijn van Noort, et al.
Clinical Pharmacology and Therapeutics
|
January 29, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease
Kelly M Mahar, Martijn van Noort, Paul van den Berg, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 2025
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia
Kelly M Mahar, Shuying Yang, Brendan Johnson, et al.
Page
of 2